These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 11072938)

  • 1. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial.
    Boaz M; Smetana S; Weinstein T; Matas Z; Gafter U; Iaina A; Knecht A; Weissgarten Y; Brunner D; Fainaru M; Green MS
    Lancet; 2000 Oct; 356(9237):1213-8. PubMed ID: 11072938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial.
    Sesso HD; Buring JE; Christen WG; Kurth T; Belanger C; MacFadyen J; Bubes V; Manson JE; Glynn RJ; Gaziano JM
    JAMA; 2008 Nov; 300(18):2123-33. PubMed ID: 18997197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study.
    Mann JF; Lonn EM; Yi Q; Gerstein HC; Hoogwerf BJ; Pogue J; Bosch J; Dagenais GR; Yusuf S;
    Kidney Int; 2004 Apr; 65(4):1375-80. PubMed ID: 15086477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial.
    Tepel M; van der Giet M; Statz M; Jankowski J; Zidek W
    Circulation; 2003 Feb; 107(7):992-5. PubMed ID: 12600912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin E supplementation and cardiovascular events in high-risk patients.
    ; Yusuf S; Dagenais G; Pogue J; Bosch J; Sleight P
    N Engl J Med; 2000 Jan; 342(3):154-60. PubMed ID: 10639540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
    Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.
    Lonn E; Bosch J; Yusuf S; Sheridan P; Pogue J; Arnold JM; Ross C; Arnold A; Sleight P; Probstfield J; Dagenais GR;
    JAMA; 2005 Mar; 293(11):1338-47. PubMed ID: 15769967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS).
    Stephens NG; Parsons A; Schofield PM; Kelly F; Cheeseman K; Mitchinson MJ
    Lancet; 1996 Mar; 347(9004):781-6. PubMed ID: 8622332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antioxidative vitamines for prevention of cardiovascular disease for patients after renal transplantation and patients with chronic renal failure.
    Schnell-Inderst P; Kossmann B; Fischereder M; Klauss V; Wasem J
    GMS Health Technol Assess; 2006 Jul; 2():Doc14. PubMed ID: 21289965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial.
    Heart Protection Study Collaborative Group
    Lancet; 2002 Jul; 360(9326):23-33. PubMed ID: 12114037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial.
    Tardif JC; McMurray JJ; Klug E; Small R; Schumi J; Choi J; Cooper J; Scott R; Lewis EF; L'Allier PL; Pfeffer MA;
    Lancet; 2008 May; 371(9626):1761-8. PubMed ID: 18502300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial.
    Lee IM; Cook NR; Gaziano JM; Gordon D; Ridker PM; Manson JE; Hennekens CH; Buring JE
    JAMA; 2005 Jul; 294(1):56-65. PubMed ID: 15998891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of fish oil and vitamin B and E supplementation with cardiovascular outcomes and mortality in people receiving haemodialysis: a review.
    Bessell E; Jose MD; McKercher C
    BMC Nephrol; 2015 Aug; 16():143. PubMed ID: 26283325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.
    Jamison RL; Hartigan P; Kaufman JS; Goldfarb DS; Warren SR; Guarino PD; Gaziano JM;
    JAMA; 2007 Sep; 298(10):1163-70. PubMed ID: 17848650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients.
    Morimoto H; Nakao K; Fukuoka K; Sarai A; Yano A; Kihara T; Fukuda S; Wada J; Makino H
    Nephrol Dial Transplant; 2005 Dec; 20(12):2775-82. PubMed ID: 16221689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial.
    Poston L; Briley AL; Seed PT; Kelly FJ; Shennan AH;
    Lancet; 2006 Apr; 367(9517):1145-54. PubMed ID: 16616557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOSIDIAL: a randomised placebo controlled trial of the effects of fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. Study design and patients' baseline characteristics.
    Zannad F; Kessler M; Grünfeld JP; Thuilliez C;
    Fundam Clin Pharmacol; 2002 Oct; 16(5):353-60. PubMed ID: 12602460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study.
    Takahashi A; Takase H; Toriyama T; Sugiura T; Kurita Y; Ueda R; Dohi Y
    Nephrol Dial Transplant; 2006 Sep; 21(9):2507-12. PubMed ID: 16766543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time course and dose response of alpha tocopherol on oxidative stress in haemodialysis patients.
    Reed A; Cho YJ; Coombes JS; Fassett RG
    BMC Nephrol; 2009 Oct; 10():32. PubMed ID: 19845969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial.
    Heinz J; Kropf S; Domröse U; Westphal S; Borucki K; Luley C; Neumann KH; Dierkes J
    Circulation; 2010 Mar; 121(12):1432-8. PubMed ID: 20231532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.